The content of this podcast is provided for general informational purposes only and is not intended as,

nor should it be considered a substitute for professional medical advice.

Oh, how I feel.

Bitchy, bitchy, bitchy, bitchy, bitchy, bitchy, bitchy, bitchy, bitchy and bitchy.

Hello, this is Karen Nicol family nurse practitioner, and you are listening to Itchy and Bitchie,

a podcast that provides answers to your many unanswered health questions.

I know most, if not all of you, know about the medications called GLP1 receptor agonists. They are all the rage in the world of weight

loss, and the most familiar of them is the brand Ozympic. Beyond obesity and type 2 diabetes, the therapeutic

potential of GLP1, which stands for glucaon-like peptide 1 receptor agonists,

extends to a range of conditions such as cardiovascular disease, liver disease, neurodegenerative disease, and substance use disorders.

For those who don't know how a GLP1 receptor agonist works, here's a brief explanation.

GLP1 is a hormone that your small intestine makes. This hormone triggers insulin release from the

pancreas, blocks glucagon, which is a hormone that your body uses to increase blood sugars as needed,

and slows stomach emptying and increases a sense of fullness after eating.

These meds mimic what our natural GLP1 hormone does for us.

So what other benefits can we get from using a GLP1 receptor agonist? Well, a phase

two clinical trial in 24 that included 156 people with a three-year or greater history of Parkinson's

disease looked for any symptom benefit of using a GLP1 agonist called Lixocinotide after one year of use.

Using a test scoring system for Parkinson's, the study showed that people treated with Lixocinotide

showed no progression of the disease, while the control group, taking a placebo treatment,

continued to progress in their disease. However, some contradictory evidence from a study was

published in February of 2025. This phase three clinical trial consisted of 194 participants,

...